UBS Reiterates Buy Rating on Moderna (MRNA) as Drastic Change to COVID-19 Vaccine Access Appears Unlikely
Tweet Send to a Friend
UBS analyst Eliana Merle reiterated a Buy rating and $70.00 price target on Moderna (NASDAQ: MRNA).The analyst commented, "We hosted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
